One last comment I would make about Zebra's excellent observations about warning signs -- patient outcomes measured by the Glasgow Coma Scale were an endpoint in most or all of Dexanabinol's trials. Professional neurologists may disagree, but I view the Glasgow scale as inherently subjective as compared to other metrics, such as visual acuity. Use of endpoints which lean subjective is another warning sign.